Cargando…

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?

Chronic lymphocytic leukemia (CLL) cells cycle between lymphoid tissue sites where they actively proliferate, and the peripheral blood (PB) where they become quiescent. Strong evidence exists for a crucial role of B cell receptor (BCR) triggering, either by (self-)antigen or by receptor auto-engagem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haselager, Marco V., Kater, Arnon P., Eldering, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578574/ https://www.ncbi.nlm.nih.gov/pubmed/33134182 http://dx.doi.org/10.3389/fonc.2020.592205

Ejemplares similares

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
por: van Attekum, Martijn HA, et al.
Publicado: (2017)

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
por: Peters, Fleur S., et al.
Publicado: (2021)

P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Montironi, Chiara, et al.
Publicado: (2023)

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia
por: Montironi, Chiara, et al.
Publicado: (2023)

Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
por: van der Straten, Lina, et al.
Publicado: (2021)

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling
por: van Attekum, MHA, et al.
Publicado: (2016)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

P595: DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Simon-Molas, Helga, et al.
Publicado: (2023)

CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis
por: van Attekum, Martijn H.A., et al.
Publicado: (2017)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

The Therapeutic Potential of Targeting NIK in B Cell Malignancies
por: Haselager, Marco V., et al.
Publicado: (2022)

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling
por: Hofland, Tom, et al.
Publicado: (2019)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
por: de Weerdt, Iris, et al.
Publicado: (2019)

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival
por: Haselager, Marco V., et al.
Publicado: (2023)

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia
por: van Attekum, M H A, et al.
Publicado: (2017)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
por: Jacobs, Chaja F., et al.
Publicado: (2021)

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
por: Baliakas, Panagiotis, et al.
Publicado: (2022)

Telomere Dysfunction in Chronic Lymphocytic Leukemia
por: Jebaraj, Billy Michael Chelliah, et al.
Publicado: (2021)

Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors
por: Martens, Anne W. J., et al.
Publicado: (2023)

NOTCH1 Aberrations in Chronic Lymphocytic Leukemia
por: Rosati, Emanuela, et al.
Publicado: (2018)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
por: Perutelli, Francesca, et al.
Publicado: (2022)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects
por: Fattizzo, Bruno, et al.
Publicado: (2020)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
por: D’Arena, Giovanni, et al.
Publicado: (2020)

Precision diagnostics in chronic lymphocytic leukemia: Past, present and future
por: Mollstedt, John, et al.
Publicado: (2023)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies
por: Sana, Ilenia, et al.
Publicado: (2021)

Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability
por: Zavacka, Kristyna, et al.
Publicado: (2021)

Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia
por: Wu, Xun, et al.
Publicado: (2021)

AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression
por: Oppezzo, Pablo, et al.
Publicado: (2021)

Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
por: Wang, Zong-Han, et al.
Publicado: (2023)

Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo
por: Spaner, David E., et al.
Publicado: (2023)

Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
por: Verma, Vivek, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n54nmm031n9upfqbdft96k4mlh